Verastem
VSTM • NASDAQ
Verastem is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Daniel W. Paterson, with a market cap of $442.7M.
CEODaniel W. Paterson
Next Earnings
Upcoming earnings announcement for Verastem
Date
Tuesday, May 12, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.46
Revenue Estimate
$22.2M
Earnings History
Past 12 earnings reports for Verastem
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Mar 4, 2026 | Q4 2025 | -$0.48Est: -$0.49 | +2.0% | $17.5MEst: $17.1M | +2.5% |  10-K |
| Nov 4, 2025 | Q3 2025 | -$0.54Est: -$0.57 | +5.3% | $11.2MEst: $5.9M | +90.1% | 10-Q |
| Aug 7, 2025 | Q2 2025 | -$0.63Est: -$0.68 | +7.4% | $2.1MEst: $6.9M | -69.2% | 10-Q |
| May 13, 2025 | Q1 2025 | -$0.79Est: -$0.61 | -29.5% | -Est: $200.0K | -100.0% | 10-Q |
| Mar 20, 2025 | Q4 2024 | -$0.60Est: -$0.81 | +25.9% | -Est: $150.0K | -100.0% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.88Est: -$0.74 | -18.9% | -Est: $50.0K | -100.0% | 10-Q |
| Aug 8, 2024 | Q2 2024 | -$0.61Est: -$0.95 | +35.8% | $10.0MEst: $50.0K | +19900.0% | 10-Q |
| May 9, 2024 | Q1 2024 | -$0.98Est: -$1.03 | +4.9% | - | — | 10-Q |
| Mar 14, 2024 | Q4 2023 | -$1.10Est: -$0.62 | -77.4% | - | — | 10-K |
| Nov 8, 2023 | Q3 2023 | -$0.71Est: -$0.84 | +15.5% | -Est: $30.0K | -100.0% | — |
| Aug 8, 2023 | Q2 2023 | -$1.06Est: -$1.07 | +0.9% | -Est: $20.0K | -100.0% | 10-Q |
| May 9, 2023 | Q1 2023 | -$1.08Est: -$0.96 | -12.5% | -Est: $20.0K | -100.0% | — |